APA (7th ed.) Citation

Delimpasi, S., Quach, H., Cavo, M., Ho, P. J., Lee, C. H., Santoro, A., . . . Dimopoulos, M. A. (2022, June). PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. HemaSphere.

Chicago Style (17th ed.) Citation

Delimpasi, S., et al. "PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA." HemaSphere Jun. 2022.

MLA (9th ed.) Citation

Delimpasi, S., et al. "PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA." HemaSphere, Jun. 2022.